<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several approaches to treat laminin alpha2 chain-deficient <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e>) in mouse models have been undertaken </plain></SENT>
<SENT sid="1" pm="."><plain>Most have shown promising results in young animals </plain></SENT>
<SENT sid="2" pm="."><plain>However, older animals have only been characterized to some extent </plain></SENT>
<SENT sid="3" pm="."><plain>Herein we analyze the lifespan of laminin alpha2 chain-deficient mice with transgenic overexpression of laminin alpha1 chain </plain></SENT>
<SENT sid="4" pm="."><plain>Further outcome measures included internalized myonuclei, heart <z:mp ids='MP_0003045'>fibrosis</z:mp>, grip strength, and serum <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase activity </plain></SENT>
<SENT sid="5" pm="."><plain>We show that laminin alpha2-chain-deficient animals that overexpress laminin alpha1 chain survive to up to 1.5-2 years of age </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, they displayed improved skeletal and heart muscle <z:mp ids='MP_0000002'>morphology</z:mp>, near-<z:mpath ids='MPATH_458'>normal</z:mpath> muscle strength, and normalized <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase levels </plain></SENT>
<SENT sid="7" pm="."><plain>Such an improvement of the dystrophic phenotype that persists to old age has not been previously demonstrated in mice </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings hold promise with regard to the efficient treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDC1A</z:e> patients in the future </plain></SENT>
</text></document>